Clinical update on linezolid in the treatment of Gram-positive bacterial infections

References

• MoutonJWJanszARThe DUEL study:a multi-center in vitro evaluation of Linezolid compared with other antibiotics in The NetherlandsClin Microbiol Infect20017948649111678931
   PubMed Web of Science ®Google Scholar
• DraghiDCSheehanDJHoganPSahmDFIn vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance programAntimicrob Agents Chemother200549125024503216304168
   PubMed Web of Science ®Google Scholar
• MutnickAHBiedenbachDJTurnidgeJDJonesRNSpectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000Diagn Microbiol Infect Dis2002431657312052631
   PubMed Web of Science ®Google Scholar
• JevittLASmithAJWilliamsPPRaneyPMMcGowanJEJrTenoverFCIn vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faeciumMicrob Drug Resist20039438939315000746
   PubMed Web of Science ®Google Scholar
• FlueggeKSupperSSiedlerABernerRAntibiotic susceptibility in neonatal invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in GermanyAntimicrob Agents Chemother200448114444444615504878
   PubMed Web of Science ®Google Scholar
• JonesRNStilwellMGHoganPASheehanDJActivity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance ProgramAntimicrob Agents Chemother20075141491149317210770
   PubMed Web of Science ®Google Scholar
• BetriuCRedondoMPalauMLComparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococciAntimicrob Agents Chemother20004471838184110858339
   PubMed Web of Science ®Google Scholar
• Kosowska-ShickKSmithKBogdanovichTEdnieLMJonesRNAppelbaumPCActivity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominisAntimicrob Agents Chemother200650124191419417043120
   PubMed Web of Science ®Google Scholar
• ZhanelGGPalatnickLNicholKABellyouTLowDEHobanDJAntimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002Antimicrob Agents Chemother20034761867187412760860
   PubMed Web of Science ®Google Scholar
• FunkeGNietznikCMinimal inhibitory concentrations of linezolid against clinical isolates of coryneform bacteriaEur J Clin Microbiol Infect Dis200524961261416175358
   PubMed Web of Science ®Google Scholar
• KlareIKonstabelCWernerGAntimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional useJ Antimicrob Chemother200759590091217369278
   PubMed Web of Science ®Google Scholar
• BowersockTLSalmonSAPortisESMICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animalsAntimicrob Agents Chemother20004451367136910770781
   PubMed Web of Science ®Google Scholar
• Brown-ElliottBAWardSCCristCJMannLBWilsonRWWallaceRJJrIn vitro activities of linezolid against multiple Nocardia speciesAntimicrob Agents Chemother20014541295129711257051
   PubMed Web of Science ®Google Scholar
• AckermannGAdlerDRodloffACIn vitro activity of linezolid against Clostridium difficileJ Antimicrob Chemother200351374374512615885
   PubMed Web of Science ®Google Scholar
• BainesSDNoelARHuscroftGSEvaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut modelJ Antimicrob Chemother20116671537154621504940
   PubMed Web of Science ®Google Scholar
• DaeschleinGHoehneCAssadianOIn vitro activity of linezolid against clinical isolates of Fusobacterium sppJ Antimicrob Chemother200658478979316905529
   PubMed Web of Science ®Google Scholar
• CitronDMMerriamCVTyrrellKLWarrenYAFernandezHGoldsteinEJIn vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteriaAntimicrob Agents Chemother20034772334233812821492
   PubMed Web of Science ®Google Scholar
• MolitorisDVäisänenMLBolañosMFinegoldSMIn vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolatesAntimicrob Agents Chemother20065051887188916641470
   PubMed Web of Science ®Google Scholar
• SmithAJHallVThakkerBGemmellCGAntimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agentsJ Antimicrob Chemother200556240740915972310
   PubMed Web of Science ®Google Scholar
• Brown-ElliottBACristCJMannLBWilsonRWWallaceRJJrIn vitro activity of linezolid against slowly growing nontuberculous MycobacteriaAntimicrob Agents Chemother20034751736173812709349
   PubMed Web of Science ®Google Scholar
• YangSCHsuehPRLaiHCHigh prevalence of antimicrobial resistance in rapidly growing mycobacteria in TaiwanAntimicrob Agents Chemother20034761958196212760874
   PubMed Web of Science ®Google Scholar
• ShinabargerDMechanism of action of the oxazolidinone antibacterial agentsExpert Opin Investig Drugs19998811951202
   PubMedGoogle Scholar
• ColcaJRMcDonaldWGWaldonDJCrosslinking in the living cell locates the site of action of oxazolidinone antibioticsJ Biol Chem200327824219722197912690106
   PubMed Web of Science ®Google Scholar
• LeachKLSwaneySMColcaJRThe site of action of oxazolidinone antibiotics in living bacteria and in human mitochondriaMol Cell200726339340217499045
   PubMed Web of Science ®Google Scholar
• JonesRNKohnoSOnoYRossJEYanagiharaKZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countriesDiagn Microbiol Infect Dis200964219120119500528
   PubMed Web of Science ®Google Scholar
• FarrellDJMendesRERossJEJonesRNLinezolid surveillance program results for 2008 (LEADER Program for 2008)Diagn Microbiol Infect Dis200965439240319913682
   PubMed Web of Science ®Google Scholar
• RossJEFarrellDJMendesRESaderHSJonesRNEight-year (2002–2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countriesJ Chemother2011232717621571621
   PubMed Web of Science ®Google Scholar
• ZurenkoGToddWMHafkinBADevelopment of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid (abstract)Proceedings of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)San Francisco, CASeptember 26–29, 1999
   Google Scholar
• GonzalesRDSchreckenbergerPCGrahamMBKelkarSDenBestenKQuinnJPInfections due to vancomycin-resistant Enterococcus faecium resistant to linezolidLancet20013579263117911323048
   PubMed Web of Science ®Google Scholar
• TsiodrasSGoldHSSakoulasGLinezolid resistance in a clinical isolate of Staphylococcus aureusLancet2001358927720720811476839
   PubMed Web of Science ®Google Scholar
• PotoskiBAAdamsJClarkeLEpidemiological profile of linezolid-resistant coagulase-negative staphylococciClin Infect Dis200643216517116779742
   PubMed Web of Science ®Google Scholar
• JonesRNFritscheTRSaderHSRossJEZyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesDiagn Microbiol Infect Dis200759219920917908617
   PubMed Web of Science ®Google Scholar
• MutnickAHEnneVJonesRNLinezolid resistance since 2001: SENTRY Antimicrobial Surveillance ProgramAnn Pharmacother200337676977412773059
   PubMed Web of Science ®Google Scholar
• MekaVGGoldHSAntimicrobial resistance to linezolidClin Infect Dis20043971010101515472854
   PubMed Web of Science ®Google Scholar
• KellySCollinsJMaguireMAn outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unitJ Antimicrob Chemother200861490190718272512
   PubMed Web of Science ®Google Scholar
• PrystowskyJSiddiquiFChosayJResistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococciAntimicrob Agents Chemother20014572154215611408243
   PubMed Web of Science ®Google Scholar
• FarrellDJMendesRERossJESaderHSJonesRNLEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United StatesAntimicrob Agents Chemother20115583684369021670176
   PubMed Web of Science ®Google Scholar
• KolaAKirschnerPGohrbandtBAn infection with linezolid-resistant S. aureus in a patient with left ventricular assist systemScand J Infect Dis200739546346517464873
   PubMed Web of Science ®Google Scholar
• DobbsTEPatelMWaitesKBMoserSAStammAMHoesleyCJNosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical centerJ Clin Microbiol20064493368337016954275
   PubMed Web of Science ®Google Scholar
• MillerKO’NeillAJWilcoxMHInghamEChopraIDelayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agentsAntimicrob Agents Chemother20085261940194418378719
   PubMed Web of Science ®Google Scholar
• KehrenbergCSchwarzSJacobsenLHansenLHVesterBA new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503Mol Microbiol20055741064107316091044
   PubMed Web of Science ®Google Scholar
• TohSMXiongLAriasCAAcquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolidMol Microbiol20076461506151417555436
   PubMed Web of Science ®Google Scholar
• WelshmanIRSissonTAJungbluthGLStalkerDJHopkinsNKLinezolid absolute bioavailability and the effect of food on oral bioavailabilityBiopharm Drug Dispos2001223919711745911
   PubMed Web of Science ®Google Scholar
• GeeTEllisRMarshallGAndrewsJAshbyJWiseRPharmacokinetics and tissue penetration of linezolid following multiple oral dosesAntimicrob Agents Chemother20014561843184611353635
   PubMed Web of Science ®Google Scholar
• SlatterJGStalkerDJFeenstraKLPharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjectsDrug Metab Dispos20012981136114511454733
   PubMed Web of Science ®Google Scholar
• StalkerDJJungbluthGLClinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterialClin Pharmacokinet200342131129114014531724
   PubMed Web of Science ®Google Scholar
• GrunderGZysset-AschmannYVollenweiderFMaierTKrähenbühlSDreweJLack of pharmacokinetic interaction between linezolid and antacid in healthy volunteersAntimicrob Agents Chemother2006501687216377669
   PubMed Web of Science ®Google Scholar
• KeelRASchaeftleinAKloftCPharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosisAntimicrob Agents Chemother20115573393339821518837
   PubMed Web of Science ®Google Scholar
• StalkerDJJungbluthGLHopkinsNKBattsDHPharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic in healthy volunteersJ Antimicrob Chemother20035151239124612668582
   PubMed Web of Science ®Google Scholar
• MacGowanAPPharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infectionsJ Antimicrob Chemother200351Suppl 2ii172512730139
   PubMed Web of Science ®Google Scholar
• MeagherAKForrestARaynerCRBirminghamMCSchentagJJPopulation pharmacokinetics of linezolid in patients treated in a compassionate-use programAntimicrob Agents Chemother200347254855312543657
   PubMed Web of Science ®Google Scholar
• AdembriCFallaniSCassettaMILinezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusionInt J Antimicrob Agents200831212212918055183
   PubMed Web of Science ®Google Scholar
• SissonTLJungbluthGLHopkinsNKAge and sex effects on the pharmacokinetics of linezolidEur J Clin Pharmacol2002571179379711868801
   PubMed Web of Science ®Google Scholar
• ClemettDMarkhamALinezolidDrugs200059481582710804037
   PubMed Web of Science ®Google Scholar
• DehghanyarPBürgerCZeitlingerMPenetration of linezolid into soft tissues of healthy volunteers after single and multiple dosesAntimicrob Agents Chemother20054962367237115917535
   PubMed Web of Science ®Google Scholar
• LoveringAMZhangJBannisterGCPenetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacementJ Antimicrob Chemother200250737712096009
   PubMed Web of Science ®Google Scholar
• Kutscha-LissbergFHeblerUMuhrGKöllerMLinezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococciAntimicrob Agents Chemother200347123964396614638510
   PubMed Web of Science ®Google Scholar
• BoselliEBreilhDRimmeléTPharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumoniaCrit Care Med20053371529153316003058
   PubMed Web of Science ®Google Scholar
• HoneybourneDTobinCJevonsGAndrewsJWiseRIntrapulmonary penetration of linezolidAntimicrob Chemother200351614311434
   Web of Science ®Google Scholar
• ConteJEJrGoldenJAKippsJZurlindenEIntrapulmonary pharmacokinetics of linezolidAntimicrob Agents Chemother20024651475148011959585
   PubMed Web of Science ®Google Scholar
• TsonaAMetallidisSForoglouNLinezolid penetration into cerebrospinal fluid and brain tissueJ Chemother2010221171920227987
   PubMed Web of Science ®Google Scholar
• BoakLMLiJSpelmanDdu CrosPNationRLRaynerCRSuccessful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitisAnn Pharmacother2006407–81451145516772405
   PubMed Web of Science ®Google Scholar
• MyrianthefsPMarkantonisSLVlachosKSerum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical PatientsAntimicrob Agents Chemother200650123971397616982782
   PubMed Web of Science ®Google Scholar
• BeerREngelhardtKWPfauslerBPharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drainsAntimicrob Agents Chemother20075137938217043116
   PubMed Web of Science ®Google Scholar
• ViaggiBPaoloADDanesiRLinezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokineticsScand J Infect Dis201143972172721585240
   PubMed Web of Science ®Google Scholar
• PrydalJIJenkinsDRLoveringAWattsAThe pharmacokinetics of linezolid in the non-inflamed human eyeBr J Ophthalmol200589111418141916234443
   PubMed Web of Science ®Google Scholar
• VázquezEGMensaJLópezYPenetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administrationAntimicrob Agents Chemother200448267067214742235
   PubMed Web of Science ®Google Scholar
• BuergerCPlockNDehghanyarPJoukhadarCKloftCPharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysisAntimicrob Agents Chemother20065072455246316801426
   PubMed Web of Science ®Google Scholar
• RaoGGStegerATobinCMlinezolid levels in pancreatic secretionsJ Antimicrob Chemother200148693193211733483
   PubMed Web of Science ®Google Scholar
• DePestelDDPeloquinCACarverPLPeritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitisPharmacotherapy200323101322132614594349
   PubMed Web of Science ®Google Scholar
• DehghanyarPBürgerCZeitlingerMPenetration of linezolid into soft tissues of healthy volunteers after single and multiple dosesAntimicrob Agents Chemother20054962367237115917535
   PubMed Web of Science ®Google Scholar
• SagirliOOnalATokerSOztunçADetermination of linezolid in human breast milk by high-performance liquid chromatography with ultraviolet detectionJ AOAC Int20099261658166220166583
   PubMed Web of Science ®Google Scholar
• WilcoxMHKitePMillsKSugdenSIn situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilmJ Antimicrob Chemother200147217117511157901
   PubMed Web of Science ®Google Scholar
• WiederholdNPCoyleEARaadIIPrinceRALewisREAntibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteraemiaJ Antimicrob Chemother200555579279515814598
   PubMed Web of Science ®Google Scholar
• BaystonRNuradeenBAshrafWFreemanBJAntibiotics for the eradication of Propionibacterium acnes biofilms in surgical infectionJ Antimicrob Chemother20076061298130117959732
   PubMed Web of Science ®Google Scholar
• LeiteBGomesFTeixeiraPSouzaCPizzolittoEOliveiraRIn vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilmsCurr Microbiol201163331331721761219
   PubMed Web of Science ®Google Scholar
• BaystonRUllasGAshrafWThe action of linezolid or vancomycin on biofilms in ventriculoperitoneal shunts in vitroAntimicrob Agents Chemother2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• HolmbergAMörgelinMRasmussenMEffectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilmsJ Antimicrob Chemother201267243343922110086
   PubMed Web of Science ®Google Scholar
• SandoeJAWysomeJWestAPHeritageJWilcoxMHMeasurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilmsJ Antimicrob Chemother200657476777016464896
   PubMed Web of Science ®Google Scholar
• BrierMEStalkerDJAronoffGRPharmacokinetics of linezolid in subjects with renal dysfunctionAntimicrob Agents Chemother20034792775278012936973
   PubMed Web of Science ®Google Scholar
• HendershotPEJungbluthGLCammarataSKHopkinsNJPharmacokinetics of linezolid in patients with liver diseaseJ Antimicrob Chemother199944Suppl A55
   Google Scholar
• FiaccadoriEMaggioreURotelliCRemoval of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failureCrit Care Med200432122437244215599148
   PubMed Web of Science ®Google Scholar
• MeyerBKornekGVNikfardjamMMultiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltrationJ Antimicrob Chemother200556117217915905303
   PubMed Web of Science ®Google Scholar
• TrotmanRLWilliamsonJCShoemakerDMSalzerWLAntibiotic dosing in critically ill adult patients receiving continuous renal replacement therapyClin Infect Dis20054181159116616163635
   PubMed Web of Science ®Google Scholar
• KearnsGLAbdel-RahmanSMBlumerJLSingle dose pharmacokinetics of linezolid in infants and childrenPediatr Infect Dis J200019121178118411144380
   PubMed Web of Science ®Google Scholar
• WiseRAndrewsJMBoswellFJAshbyJPThe in-vitro activity of linezolid (U-100766) and tentative breakpointsJ Antimicrob Chemother199842672172810052894
   PubMed Web of Science ®Google Scholar
• BowkerKEWoottonMHoltHAMacGowanAPIn vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patientsJ Antimicrob Chemother200249357858011864965
   PubMed Web of Science ®Google Scholar
• ZurenkoGEYagiBHSchaadtRDIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agentsAntimicrob Agents Chemother19964048398458849237
   PubMed Web of Science ®Google Scholar
• RybakMJCappellettyDMMoldovanTAeschlimannJRKaatzGWComparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faeciumAntimicrob Agents Chemother19984237217249517963
   PubMed Web of Science ®Google Scholar
• WilcoxMNathwaniDDrydenMLinezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infectionsJ Antimicrob Chemother200453233534414729745
   PubMed Web of Science ®Google Scholar
• WilcoxMHTackKJBouzaEComplicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 studyClin Infect Dis200948220321219072714
   PubMed Web of Science ®Google Scholar
• FalagasMESiemposIIVardakasKZLinezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trialsLancet Infect Dis200881536618156089
   PubMed Web of Science ®Google Scholar
• BeibeiLYunCMengliCNanBXuhongYRuiWLinezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trialsInt J Antimicrob Agents201035131219900794
   PubMed Web of Science ®Google Scholar
• JangHCKimSHKimKHSalvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenemClin Infect Dis200949339540119569970
   PubMed Web of Science ®Google Scholar
• JaureguiLEBabazadehSSeltzerERandomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infectionsClin Infect Dis200541101407141516231250
   PubMed Web of Science ®Google Scholar
• WeigeltJItaniKStevensDLauWDrydenMKnirschCLinezolid CSSTI Study GroupLinezolid versus vancomycin in treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother20054962260226615917519
   PubMed Web of Science ®Google Scholar
• StevensDLSmithLGBrussJBRandomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother200044123408341311083648
   PubMed Web of Science ®Google Scholar
• BounthavongMHsuDIEfficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysisCurr Med Res Opin201026240742120001574
   PubMed Web of Science ®Google Scholar
• SaroglouMTryfonSIsmailosGPharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusionJ Inflamm (Lond)201072220482752
   PubMed Web of Science ®Google Scholar
• San PedroGSCammarataSKOliphantTHTodiscoTLinezolid Community-Acquired Pneumonia Study GroupLinezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumoniaScand J Infect Dis2002341072072812477321
   PubMedGoogle Scholar
• WalkeyAJO’DonnellMRWienerRSLinezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trialsChest201113951148115520864609
   PubMed Web of Science ®Google Scholar
• WunderinkRGNiedermanMSKollefMHLinezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled studyClin Infect Dis201254562162922247123
   PubMed Web of Science ®Google Scholar
• RanaBButcherIGrigorisPMurnaghanCSeatonRATobinCMLinezolid penetration into osteo-articular tissuesJ Antimicrob Chemother200250574775012407135
   PubMed Web of Science ®Google Scholar
• HowdenBPWardPBCharlesPGTreatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibilityClin Infect Dis200438452152814765345
   PubMed Web of Science ®Google Scholar
• AneziokoroCOCannonJPPachuckiCTLentinoJRThe effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitisJ Chemother200517664365016433195
   PubMed Web of Science ®Google Scholar
• RaynerCRBaddourLMBirminghamMCNordenCMeagherAKSchentagJJLinezolid in the treatment of osteomyelitis: results of compassionate use experienceInfection200432181415007736
   PubMed Web of Science ®Google Scholar
• DaileyCFDileto-FangCLBuchananLVEfficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20014582304230811451689
   PubMed Web of Science ®Google Scholar
• PatelRRouseMSPiperKESteckelbergJMLinezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditisAntimicrob Agents Chemother200145262162311158767
   PubMed Web of Science ®Google Scholar
• MunozPRodríguez-CreixémsMMorenoMMarínMRamalloVBouzaEGAME Study GroupLinezolid therapy for infective endocarditisClin Microbiol Infect200713221121517328738
   PubMed Web of Science ®Google Scholar
• TsigrelisCSinghKVCoutinhoTDMurrayBEBaddourLMVancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factorsJ Clin Microbiol200745263163517182759
   PubMed Web of Science ®Google Scholar
• CornePMarchandinHMaciaJCJonquetOTreatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolidScand J Infect Dis20053711–1294694916308242
   PubMed Web of Science ®Google Scholar
• FalagasMEMantaKGNtzioraFVardakasKZLinezolid for the treatment of patients with endocarditis: a systematic review of the published evidenceJ Antimicrob Chemother200658227328016735427
   PubMed Web of Science ®Google Scholar
• JacquelineCAsserayNBatardEIn vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureusInt J Antimicrob Agents200424439339615380267
   PubMed Web of Science ®Google Scholar
• NagashimaGOkamotoNOkudaMEffect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case reportJ Infect Chemother200814214715018622679
   PubMedGoogle Scholar
• KruegerWAKottlerBWillBEHeiningerAGuggenbergerHUnertlKETreatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolidJ Clin Microbiol200442292993214766894
   PubMed Web of Science ®Google Scholar
• CastroPSorianoAEscrichCVillalbaGSarasaMMensaJLinezolid treatment of ventriculoperitoneal shunt infection without implant removalEur J Clin Microbiol Infect Dis200524960360616187055
   PubMed Web of Science ®Google Scholar
• TsujiYHirakiYMatsumotoKPharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitisScand J Infect Dis20114311–1298298521851332
   PubMed Web of Science ®Google Scholar
• ZeanaCKubinCJDella-LattaPHammerSMVancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literatureClin Infect Dis200133447748211462183
   PubMed Web of Science ®Google Scholar
• FaellaFPaglianoPFuscoUAttanasioVConteMCombined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strainsClin Microbiol Infect200612439139416524418
   PubMed Web of Science ®Google Scholar
• RamírezPSahuquilloJMCortésCKotPBonastreJMLinezolid as rescue therapy for pneumococcal meningitisIntensive Care Med200733592492517431583
   PubMed Web of Science ®Google Scholar
• LeitiOGrossJWTuazonCUTreatment of brain abscess caused by Listeria monocytogenes in a patient with allergy to penicillin and trimethoprim-sulfamethoxazoleClin Infect Dis200540690790815736033
   PubMed Web of Science ®Google Scholar
• ViganòSMEdefontiAFerraressoMSuccessful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipientPediatr Nephrol20052081186118815947983
   PubMed Web of Science ®Google Scholar
• JaksicBMartinelliGPerez-OteyzaJHartmanCSLeonardLBTackKJEfficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancerClin Infect Dis200642559760716447103
   PubMed Web of Science ®Google Scholar
• NanniniECKeatingMBinstockPSamonisGKontoyiannisDPSuccessful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquineJ Infect200244320120312099753
   PubMed Web of Science ®Google Scholar
• KyleSDPorterWMMycobacterium chelonae infection successfully treated with oral clarithromycin and linezolidBr J Dermatol20041515110115541095
   PubMed Web of Science ®Google Scholar
• NtzioraFFalagasMELinezolid for the treatment of patients with mycobacterial infections a systematic reviewInt J Tuberc Lung Dis200711660661117519090
   PubMed Web of Science ®Google Scholar
• RubinsteinECammarataSOliphantTWunderinkRLinezolid Nosocomial Pneumonia Study GroupLinezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter studyClin Infect Dis200132340241211170948
   PubMed Web of Science ®Google Scholar
• StevensDLHerrDLampirisHHuntJLBattsDHHafkinBLinezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infectionsClin Infect Dis200234111481149012015695
   PubMed Web of Science ®Google Scholar
• RubinsteinEIsturizRStandifordHCWorldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studiesAntimicrob Agents Chemother20034761824183112760854
   PubMed Web of Science ®Google Scholar
• KaplanSLDevilleJGYogevRLinezolid versus vancomycin for treatment of resistant Gram-positive infections in childrenPediatr Infect Dis J200322867768612913766
   PubMed Web of Science ®Google Scholar
• FalagasMEVardakasKZBenefit-risk assessment of linezolid for serious gram-positive bacterial infectionsDrug Saf200831975376818707190
   PubMed Web of Science ®Google Scholar
• CawleyMJLipkaOIntravenous linezolid administered orally: a novel desensitization strategyPharmacotherapy200626456356816553517
   PubMed Web of Science ®Google Scholar
• BishopEMelvaniSHowdenBPCharlesPGGraysonMLGood clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patientsAntimicrob Agents Chemother20065041599160216569895
   PubMed Web of Science ®Google Scholar
• KelleyWReshBGoldenbergG, Linezolid-induced purpuric medication reactionJ Cutan Pathol200936779379519519611
   PubMed Web of Science ®Google Scholar
• EspositoLKamarNGuilbeau-FrugierCMehrenbergerMModestoARostaingLLinezolid-induced interstitial nephritis in a kidney-transplant patientClin Nephrol200768532732918044266
   PubMed Web of Science ®Google Scholar
• SavardSDesmeulesSRiopelJAgharaziiMLinezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndromeAm J Kidney Dis2009546e17e2019733945
   PubMed Web of Science ®Google Scholar
• ApodacaAARakitaRMLinezolid-induced lactic acidosisN Engl J Med2003348868712510056
   PubMed Web of Science ®Google Scholar
• SuECrowleyKCarcilloJAMichaelsMGLinezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in childrenPediatr Infect Dis J201130980480621852764
   PubMed Web of Science ®Google Scholar
• ScottonPFuserRTorresanSEarly linezolid-associated lactic acidosis in a patient treated for tuberculous spondylodiscitisInfection200836438738818642110
   PubMed Web of Science ®Google Scholar
• ContouDFichetJGrimaldiDCariouAEarly life-threatening lactic acidosis following a single infusion of linezolidInt J Antimicrob Agents2011381848521482079
   PubMed Web of Science ®Google Scholar
• PalenzuelaLHahnNMNelsonRPJrDoes linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?Clin Infect Dis20054012e113e11615909253
   PubMed Web of Science ®Google Scholar
• GarrabouGSorianoALópezSReversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemiaAntimicrob Agents Chemother200751396296717194826
   PubMed Web of Science ®Google Scholar
• CarsonJCerdaJChaeJHHiranoMMaggiorePSevere lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphismPharmacotherapy200727577177417461714
   PubMed Web of Science ®Google Scholar
• FrenchGSafety and tolerability of linezolidJ Antimicrob Chemother200351Suppl 2ii455312730142
   PubMedGoogle Scholar
• MonsonTSchichmanSAZentCSLinezolid-induced pure red blood cell aplasiaClin Infect Dis2002353E29E3112115113
   PubMed Web of Science ®Google Scholar
• AttassiKHershbergerEAlamRZervosMJThrombocytopenia associated with linezolid therapyClin Infect Dis200234569569811803505
   PubMed Web of Science ®Google Scholar
• GersonSLKaplanSLBrussJBHematologic effects of linezolid: summary of clinical experienceAntimicrob Agents Chemother20024682723272612121967
   PubMed Web of Science ®Google Scholar
• NasrawaySAShorrAFKuterDJO’GradyNLeVHCammarataSKLinezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin useClin Infect Dis200337121609161614689341
   PubMed Web of Science ®Google Scholar
• WeigeltJItaniKStevensDLauWDrydenMKnirschCLinezolid CSSTI Study GroupLinezolid versus vancomycin in treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother20054962260226615917519
   PubMed Web of Science ®Google Scholar
• BernsteinWBTrottaRFRectorJTTjadenJABarileAJMechanisms for linezolid-induced anemia and thrombocytopeniaAnn Pharmacother200337451752012659607
   PubMed Web of Science ®Google Scholar
• OrrickJJJohnsTJanelleJRamphalRThrombocytopenia secondary to linezolid administration: what is the risk?Clin Infect Dis200235334834912115111
   PubMed Web of Science ®Google Scholar
• BirminghamMCRaynerCRMeagherAKFlavinSMBattsDHSchentagJJLinezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use programClin Infect Dis200336215916812522747
   PubMed Web of Science ®Google Scholar
• KuterDJTillotsonGSHematologic effects of antimicrobials: focus on the oxazolidinone linezolidPharmacotherapy200181010101311718489
   PubMed Web of Science ®Google Scholar
• LinYHWuVCTsaiIJHigh frequency of linezolid-associated thrombocytopenia among patients with renal insufficiencyInt J Antimicrob Agents200628434535116935472
   PubMed Web of Science ®Google Scholar
• HirakiYTsujiYMatsumotoKMoritaKKamimuraHKarubeYInfluence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobinAm J Med Sci2011342645646021681075
   PubMed Web of Science ®Google Scholar
• TsujiYHirakiYMatsumotoKThrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunctionJ Infect Chemother2011171707520582446
   PubMed Web of Science ®Google Scholar
• CohenNMihuCNSeoSKHematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantationBiol Blood Marrow Transplant200915101337134119747643
   PubMed Web of Science ®Google Scholar
• De BusLDepuydtPLibbrechtLSevere drug-induced liver injury associated with prolonged use of linezolidJ Med Toxicol20106332232620358416
   PubMedGoogle Scholar
• BresslerAMZimmerSMGilmoreJLSomaniJPeripheral neuropathy associated with prolonged use of linezolidLancet Infect Dis20044852853115288827
   PubMed Web of Science ®Google Scholar
• LegoutLSennevilleEGomelJJYazdanpanahYMoutonYLinezolid-induced neuropathyClin Infect Dis200438576776814986270
   PubMed Web of Science ®Google Scholar
• RuckerJCHamiltonSRBardensteinDIsadaCMLeeMSLinezolid-associated toxic optic neuropathyNeurology200666459559816505322
   PubMed Web of Science ®Google Scholar
• JavaheriMKhuranaRNO’hearnTMLaiMMSadunAALinezolid-induced optic neuropathy: a mitochondrial disorder?Br J Ophthalmol200791111111517179125
   PubMed Web of Science ®Google Scholar
• JoshiLTaylorSRLargeOYacoubSLightmanSA case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemiaClin Infect Dis2009487e73e7419231981
   PubMed Web of Science ®Google Scholar
• ThaiXCBruno-MurthaLABell’s palsy associated with linezolid therapy: case report and review of neuropathic adverse eventsPharmacotherapy20062681183118916863496
   PubMed Web of Science ®Google Scholar
• WynaldaMAHauerMJWienkersLCOxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomesDrug Metab Dispos20002891014101710950842
   PubMed Web of Science ®Google Scholar
• HendershotPEAntalEJWelshmanIRBattsDHHopkinsNKLinezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBrJ Clin Pharmacol200141556357211361053
   PubMed Web of Science ®Google Scholar
• WigenCLGoetzMBSerotonin syndrome and linezolidClin Infect Dis200234121651165212032904
   PubMed Web of Science ®Google Scholar
• BergeronLBouléMPerreaultSSerotonin toxicity associated with concomitant use of linezolidAnn Pharmacother200539595696115827071
   PubMed Web of Science ®Google Scholar
• HuangVGortneyJSRisk of serotonin syndrome with concomitant administration of linezolid and serotonin agonistsPharmacotherapy200626121784179317125439
   PubMed Web of Science ®Google Scholar
• ButterfieldJMLawrenceKRReismanAHuangDBThompsonCALodiseTPComparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial dataJ Antimicrob Chemother201267249450222139199
   PubMed Web of Science ®Google Scholar
• LawrenceKRAdraMGillmanPKSerotonin toxicity associated with the use of linezolid: a review of postmarketing dataClin Infect Dis200642111578158316652315
   PubMed Web of Science ®Google Scholar
• BounthavongMZargarzadehAHsuDIVannessDJCost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesisValue Health201114563163921839399
   PubMed Web of Science ®Google Scholar
• SchürmannDSorensenSVDe CockEDuttaguptaSReschACost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in GermanyEur J Health Econ2009101657918437437
   PubMed Web of Science ®Google Scholar
• De CockEKruegerWASorensenSCost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in GermanyInfection200937212313219277465
   PubMed Web of Science ®Google Scholar
• PatanwalaAEErstadBLNixDECost-effectiveness of linezolid and vancomycin in the treatment of surgical site infectionsCurr Med Res Opin200723118519317257479
   PubMed Web of Science ®Google Scholar